PDT Partners LLC Acquires 226,513 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

PDT Partners LLC raised its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 176.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 354,958 shares of the company’s stock after acquiring an additional 226,513 shares during the quarter. 10x Genomics makes up about 0.5% of PDT Partners LLC’s portfolio, making the stock its 28th biggest position. PDT Partners LLC owned approximately 0.29% of 10x Genomics worth $5,097,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of TXG. FMR LLC grew its stake in 10x Genomics by 0.6% during the 4th quarter. FMR LLC now owns 13,454,434 shares of the company’s stock worth $193,206,000 after buying an additional 86,455 shares during the last quarter. ARK Investment Management LLC grew its stake in shares of 10x Genomics by 11.1% during the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock worth $171,517,000 after acquiring an additional 1,193,712 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of 10x Genomics during the fourth quarter valued at about $26,308,000. Barclays PLC raised its position in shares of 10x Genomics by 31.3% in the 4th quarter. Barclays PLC now owns 790,957 shares of the company’s stock valued at $11,357,000 after purchasing an additional 188,421 shares during the last quarter. Finally, Trexquant Investment LP boosted its stake in 10x Genomics by 196.2% in the 4th quarter. Trexquant Investment LP now owns 594,611 shares of the company’s stock worth $8,539,000 after purchasing an additional 393,854 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

10x Genomics Trading Up 2.2 %

NASDAQ TXG opened at $8.48 on Tuesday. The stock has a fifty day simple moving average of $9.40 and a 200-day simple moving average of $12.98. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $29.37. The stock has a market cap of $1.04 billion, a PE ratio of -5.58 and a beta of 2.01.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Research analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Insider Transactions at 10x Genomics

In related news, Director Alan Mateo acquired 40,000 shares of 10x Genomics stock in a transaction dated Friday, February 21st. The shares were acquired at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the purchase, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. The trade was a 184.41 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares of the company’s stock, valued at $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 10.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Leerink Partnrs cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. UBS Group dropped their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Morgan Stanley cut their price objective on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Barclays dropped their target price on 10x Genomics from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Finally, JPMorgan Chase & Co. reduced their target price on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.